Clinical Trial Update: FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for FR901228 in unresectable stage III or stage IV malignant melanoma (melanoma) has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Melanoma

Drugs mentioned

• FR901228 (romidepsin)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Malignant Melanoma, Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2016-03-02